Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Glaxo-Vertex Study Tests Anti-HIV Drugs

May 17, 2006

On Tuesday, GlaxoSmithKline PLC (GSK) and Vertex Pharmaceuticals Inc. said early results from a clinical study show their HIV drug Lexiva is comparable to Abbott Laboratories Inc.'s combination drug Kaletra. The study's 887 patients received twice a day either Lexiva (700 mg) along with ritonavir (100 mg), the active ingredient in Abbott's Norvir, or Kaletra (400 mg) with ritonavir (100 mg). Once a day, patients in both groups received abacavir (600 mg) and lamivudine (300 mg), the active ingredients in GSK's HIV drugs Ziagen and Epivir. After 48 weeks, 73 percent of Lexiva patients achieved suppression of HIV replication, compared to 71 percent of the Kaletra patients, according to the study.

Back to other news for May 17, 2006

Adapted from:
Associated Press
05.16.06


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement